ClinicalTrials.gg
CompletedNCT01855789Updated Dec 26, 2017Results posted

A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX

A Phase 3 interventional study of Tocilizumab (TCZ) and Methotrexate (MTX) in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 155 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-26.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
718
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
7th of 113
718 · median 130
Started
2013
with 4 others
Phase 3
47 of 113
1 open now
Registered
71st of 113
by date
Lead sponsor
28 of 113
Hoffmann-La Roche

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 7th largest by enrollment, is one of 5 that started in 2013, is one of 47 in phase 3, and was the 71st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This randomized, multicenter, double-blind, parallel group study will evaluate the impact of MTX discontinuation on the efficacy of SC TCZ in participants with moderate to severe active rheumatoid arthritis who have an inadequate response to current MTX therapy. Participants will initiate treatment with TCZ weekly or every 2 weeks along with MTX at a stable dose orally in an open-label manner for 24 weeks. Participants with a disease activity score based on 28 joints (DAS28) less than or equal to (\</=) 3.2 at Week 24, will be randomized to either continue receiving a stable dose of MTX or to switch to matching placebo up to Week 52. Participants without a DAS28 score \</=3.2 at Week 24, will continue the same treatment in a non-randomized open-label manner up to Week 52.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight \</=150 kg
  • Active moderate to severe rheumatoid arthritis (DAS28 >/=4.4) according to the revised 1987 ACR criteria at screening and baseline (prior to treatment on Day 1)
  • Currently receiving oral MTX for at least 24 weeks and on a stable oral dose of at least 15 mg/week for at least 6 weeks prior to treatment (Day 1), with the following exception: a stable dose of at least 10 mg/week is allowed for participants with a body weight \<50 kg or calculated (or ) \<60 milliliters per minute (mL/min)
  • History of parenteral (SC or intramuscular [IM]) MTX is allowed, but not within 6 weeks prior to treatment (Day 1). Participants must not have a documented, intolerance to oral MTX and must be receiving oral MTX at a dose of 15 mg/week for at least 6 weeks prior to treatment (Day 1)
  • Participants who have received one prior anti-tumor necrosis factor (TNF) must have discontinued etanercept, infliximab, certolizumab, adalimumab, or golimumab for at least 6 months prior to screening
  • Oral must have been \</=10 mg/day prednisone (or equivalent) and stable for at least 25 out of 28 days prior to treatment (Day 1)
  • Participants receiving treatment on an outpatient basis

Exclusion criteria

Exclusion Criteria:

  • Documented medical history of significant intolerance to oral MTX >/=15 mg/week
  • Participants receiving other (non-MTX) disease modifying anti-rheumatic drugs (DMARDs) within 8 weeks of screening
  • Previous treatment with abatacept, rituximab, tofacitinib, or anakinra
  • Treatment with parenteral within 4 weeks prior to treatment
  • Previous treatment with cell-depleting therapies or alkylating agents
  • Previous treatment with TCZ
  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery during the study
  • Rheumatic disease other than rheumatoid arthritis
  • Non-rheumatic active autoimmune diseases (for example, inflammatory bowel diseases, psoriasis, multiple sclerosis)
  • Prior history of or current inflammatory joint disease other than rheumatoid arthritis
  • Functional Class IV according to the revised (1987) ACR criteria for rheumatoid arthritis
  • History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
  • Evidence of significant uncontrolled concomitant diseases; uncontrolled disease states where flares are commonly treated with oral or parenteral corticosteroids
  • Active current or history of recurrent infection, or any major episode of infection requiring hospitalization or treatment with intravenous antibiotics within 4 weeks prior to screening or oral antibiotics within 2 weeks prior to screening
  • Active tuberculosis requiring treatment within the previous 3 years
  • History of or currently active primary or secondary immunodeficiency
  • Pregnant or breast-feeding women
  • Positive for or infection
  • For potential MRI substudy participants: the presence of any metal-containing device or object in the body
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
718 participants (actual)

Study arms

  • Experimental
    Non-Randomized Participants (TCZ + MTX)

    All participants will receive initial treatment with open-label TCZ + MTX. Participants who complete 24-week treatment with open-label TCZ + MTX and did not achieve a DAS28 score \</=3.2 at Week 24, will continue receiving TCZ + MTX in open label manner up to Week 52.

    Drug: Tocilizumab (TCZ) · Drug: Methotrexate (MTX)

  • Experimental
    Randomized Participants (TCZ + MTX)

    Participants who complete the initial 24-week treatment with open-label TCZ + MTX and achieve a DAS28 score \</=3.2 at Week 24, will be randomized to receive TCZ along with MTX up to Week 52.

    Drug: Tocilizumab (TCZ) · Drug: Methotrexate (MTX)

  • Active comparator
    Randomized Participants (TCZ + PBO)

    Participants who complete the initial 24-week treatment with open-label TCZ + MTX and achieve a DAS28 score \</=3.2 at Week 24, will be randomized to receive TCZ along with MTX matched placebo (PBO) up to Week 52.

    Drug: Tocilizumab (TCZ) · Drug: Placebo (PBO)

Interventions

  • TCZ will be administered at a dose of 162 milligrams (mg) via SC injection weekly (if body weight is greater than or equal to \[\>/=\] 100 kilograms \[kg\]) or every 2 weeks (if body weight was less than \[\<\] 100 kg).

    Also known as: Actemra

  • MTX will be administered at a stable dose (15 mg to 25 mg per week) orally.

  • DrugPlacebo (PBO)

    PBO matching to MTX will be administered orally.

06

What researchers measure

Primary outcomes

  1. Change From Week 24 in Disease Activity Score Based on 28 Joints (DAS28) Score at Week 40

    The DAS28 was derived from assessments of erythrocyte sedimentation rate (ESR) measured in millimeters per hour (mm/h), tender joint count on 28 joints (TJC28), swollen joint count on 28 joints (SJC28), and Patient's Global Assessment of disease activity according to 100--millimeter (mm) Visual Analog Scale (VAS). DAS28 score was calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. DAS28 score could range from 0 to 10, where higher score represented higher disease activity. The change from Week 24 to Week 40 was averaged among all participants, where negative changes indicated an improvement in disease activity.

    Time frame: Week 24, Week 40

Secondary outcomes

  1. Percentage of Participants Achieving 20% Improvement in American College of Rheumatology (ACR20) Response

    The ACR20 response at any time was defined as \>/=20% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 20% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via a Health Assessment Questionnaire-Disability Index (HAQ-DI), and 5) Acute phase reactant (ESR in mm/h or C-Reactive Protein \[CRP\] in milligrams per deciliter \[mg/dL\]).

    Time frame: Weeks 24, 40, and 52

  2. Percentage of Participants Achieving 50% Improvement in American College of Rheumatology (ACR50) Response

    The ACR50 response at any time was defined as \>/=50% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 50% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/dL).

    Time frame: Weeks 24, 40, and 52

  3. Percentage of Participants Achieving 70% Improvement in American College of Rheumatology (ACR70) Response

    The ACR70 response at any time was defined as \>/=70% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 70% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/dL).

    Time frame: Weeks 24, 40, and 52

  4. Percentage of Participants With >/=1.2 Points Increase (Worsening) From Week 24 in DAS28 Score at Week 40 and 52

    The DAS28 was derived from assessments of ESR measured in mm/h, TJC28, SJC28, and Patient's global assessment of disease activity according to 100-mm VAS. DAS28 score was calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. DAS28- score could range from 0 to 10, where higher score represented higher disease activity.

    Time frame: Week 24, 40, and 52

  5. Percentage of Participants With DAS28 Score <2.6 (DAS28 Remission)

    The DAS28 was derived from assessments of ESR measured in mm/h, TJC28, SJC28, and Patient's global assessment of disease activity according to 100-mm VAS. DAS28 score was calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. DAS28 score could range from 0 to 10, where higher score represented higher disease activity.

    Time frame: Week 40, Week 52

  6. Percentage of Participants With DAS28 Score </=3.2 (Low DAS28)

    The DAS28 was derived from assessments of ESR measured in mm/h, TJC28, SJC28, and Patient's global assessment of disease activity according to 100-mm VAS. DAS28 score was calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. DAS28-ESR score could range from 0 to 10, where higher score represented higher disease activity.

    Time frame: Week 40, Week 52

  7. Change From Week 24 in Bone Erosion Score at Week 40 for Participants in the Magnetic Resonance Imaging (MRI) Substudy

    Bones from the wrist regions (carpal bones, distal radius, distal ulna, and metacarpal bases) and the metacarpophalangeal (MCP) joints (metacarpal heads and phalangeal bases) were assessed for erosion via MRI and scored separately based on the proportion of eroded bone compared to the 'assessed bone volume' judged from all available images. Scoring ranged from 0 (no erosion) to 10 (91-100%). Results were summed, resulting in scores from 0 to 80 for the wrist region, 0 to 150 for the MCP joints, and 0 to 230 on aggregate. A negative value for change from Week 24 in bone erosion score indicated an improvement.

    Time frame: Weeks 24, Week 40

  8. Percentage of Participants With Anti-Therapeutic Antibodies (ATA) to TCZ

    Percentage of participants with positive results for ATA against TCZ at Baseline and at any of the post-baseline assessment time-points was reported. Participants positive at any post-baseline time points were participants who had no positivity at baseline for the same assay.

    Time frame: Baseline, Post-baseline (assessed at Weeks 12, 24, 36, 52 and at follow up [Week 60])

  9. Mean TCZ Serum Concentration

    Time frame: Baseline, Weeks 12, 24, 36, 52 and follow up (Week 60)

  10. Mean Soluble Interleukin-6 (IL-6) Receptor Concentration

    Time frame: Baseline, Weeks 12, 24, 36, 52 and follow up (Week 60)

07

Results

Posted Dec 26, 2017

Participant flow

1) Baseline up to Week 24
Participant flow — 1) Baseline up to Week 24
MilestonePeriod 1: All Participants (TCZ + MTX)Period 2: Randomized Participants (TCZ + MTX)Period 2: Randomized Participants (TCZ + PBO)Period 2: Non-Randomized Participants (TCZ + MTX)
Started718000
Completed602000
Not completed116000
Withdrew: Adverse event37000
Withdrew: Death2000
Withdrew: Lack of efficacy16000
Withdrew: Lost to follow-up11000
Withdrew: Protocol violation4000
Withdrew: Withdrawal by subject31000
Withdrew: Physician decision4000
Withdrew: Pregnancy1000
Withdrew: Participant non-compliance3000
Withdrew: Sponsor decision3000
Withdrew: Other4000
2) Week 24 up to End of Study
Participant flow — 2) Week 24 up to End of Study
MilestonePeriod 1: All Participants (TCZ + MTX)Period 2: Randomized Participants (TCZ + MTX)Period 2: Randomized Participants (TCZ + PBO)Period 2: Non-Randomized Participants (TCZ + MTX)
Started0147147308
Completed0132129250
Not completed0151858
Withdrew: Adverse event04521
Withdrew: Serious hypersensitivity reaction0001
Withdrew: Lack of efficacy02516
Withdrew: Lost to follow-up0114
Withdrew: Protocol violation0001
Withdrew: Withdrawal by subject0758
Withdrew: Physician decision0024
Withdrew: Participant non-compliance0101
Withdrew: Sponsor decision0001
Withdrew: Other0001

Outcome measures

PrimaryChange From Week 24 in Disease Activity Score Based on 28 Joints (DAS28) Score at Week 40

The DAS28 was derived from assessments of erythrocyte sedimentation rate (ESR) measured in millimeters per hour (mm/h), tender joint count on 28 joints (TJC28), swollen joint count on 28 joints (SJC28), and Patient's Global Assessment of disease activity according to 100--millimeter (mm) Visual Analog Scale (VAS). DAS28 score was calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. DAS28 score could range from 0 to 10, where higher score represented higher disease activity. The change from Week 24 to Week 40 was averaged among all participants, where negative changes indicated an improvement in disease activity.

Time frame:
Week 24, Week 40
Reported as:
Mean · units on a scale
Change From Week 24 in Disease Activity Score Based on 28 Joints (DAS28) Score at Week 40
units on a scalePeriod 2: Randomized Participants (TCZ + MTX)Period 2: Randomized Participants (TCZ + PBO)
Week 242.13 ± 0.8162.11 ± 0.822
Change at Week 400.15 ± 1.1270.48 ± 1.275
Statistical analysis
  • Period 2: Randomized Participants (TCZ + MTX) vs Period 2: Randomized Participants (TCZ + PBO) · Estimated mean difference: 0.318 · 95% CI 0.045 to 0.592
SecondaryPercentage of Participants Achieving 20% Improvement in American College of Rheumatology (ACR20) Response

The ACR20 response at any time was defined as \>/=20% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 20% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via a Health Assessment Questionnaire-Disability Index (HAQ-DI), and 5) Acute phase reactant (ESR in mm/h or C-Reactive Protein \[CRP\] in milligrams per deciliter \[mg/dL\]).

Time frame:
Weeks 24, 40, and 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 20% Improvement in American College of Rheumatology (ACR20) Response
percentage of participantsPeriod 2: Randomized Participants (TCZ + MTX)Period 2: Randomized Participants (TCZ + PBO)
Week 2491.2 ± 0.81683.0 ± 0.822
Week 4078.9 ± 1.12768.7 ± 1.275
Week 5274.165.3
Statistical analysis
  • Period 2: Randomized Participants (TCZ + MTX) vs Period 2: Randomized Participants (TCZ + PBO) · Cochran-Mantel-Haenszel · p = 0.0746 · Acr 20 response rate difference: -10.2 · 95% CI -20.2 to -0.2Observed difference in percentages (TCZ + PBO minus TCZ + MTX) and the asymptotic Wald 95% CI is presented.
  • Period 2: Randomized Participants (TCZ + MTX) vs Period 2: Randomized Participants (TCZ + PBO) · Cochran-Mantel-Haenszel · p = 0.1159 · Acr 20 response rate difference: -8.8 · 95% CI -19.3 to 1.6Observed difference in percentages (TCZ + PBO minus TCZ + MTX) and the asymptotic Wald 95% CI is presented.
  • Period 2: Randomized Participants (TCZ + MTX) vs Period 2: Randomized Participants (TCZ + PBO) · Acr 20 response rate difference: -8.2 · 95% CI -15.8 to -0.6Observed difference in percentages (TCZ + PBO minus TCZ + MTX) and the asymptotic Wald 95% CI is presented.
SecondaryPercentage of Participants Achieving 50% Improvement in American College of Rheumatology (ACR50) Response

The ACR50 response at any time was defined as \>/=50% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 50% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/dL).

Time frame:
Weeks 24, 40, and 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 50% Improvement in American College of Rheumatology (ACR50) Response
percentage of participantsPeriod 2: Randomized Participants (TCZ + MTX)Period 2: Randomized Participants (TCZ + PBO)
Week 2474.1 ± 0.81663.3 ± 0.822
Week 4063.9 ± 1.12750.3 ± 1.275
Week 5262.647.6
Statistical analysis
  • Period 2: Randomized Participants (TCZ + MTX) vs Period 2: Randomized Participants (TCZ + PBO) · Cochran-Mantel-Haenszel · p = 0.0377 · Acr 50 response rate difference: -13.6 · 95% CI -24.8 to -2.4Observed difference in percentages (TCZ + PBO minus TCZ + MTX) and the asymptotic Wald 95% CI is presented.
  • Period 2: Randomized Participants (TCZ + MTX) vs Period 2: Randomized Participants (TCZ + PBO) · Cochran-Mantel-Haenszel · p = 0.0130 · Acr 50 response rate difference: -15.0 · 95% CI -26.2 to -3.7Observed difference in percentages (TCZ + PBO minus TCZ + MTX) and the asymptotic Wald 95% CI is presented.
  • Period 2: Randomized Participants (TCZ + MTX) vs Period 2: Randomized Participants (TCZ + PBO) · Acr 50 response rate difference: -10.9 · 95% CI -21.4 to -0.4Observed difference in percentages (TCZ + PBO minus TCZ + MTX) and the asymptotic Wald 95% CI is presented.
SecondaryPercentage of Participants Achieving 70% Improvement in American College of Rheumatology (ACR70) Response

The ACR70 response at any time was defined as \>/=70% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 70% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/dL).

Time frame:
Weeks 24, 40, and 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 70% Improvement in American College of Rheumatology (ACR70) Response
percentage of participantsPeriod 2: Randomized Participants (TCZ + MTX)Period 2: Randomized Participants (TCZ + PBO)
Week 2445.6 ± 0.81637.4 ± 0.822
Week 4042.2 ± 1.12734.0 ± 1.275
Week 5248.336.7
Statistical analysis
  • Period 2: Randomized Participants (TCZ + MTX) vs Period 2: Randomized Participants (TCZ + PBO) · Cochran-Mantel-Haenszel · p = 0.3599 · Acr 70 response rate difference: -8.2 · 95% CI -19.2 to 2.9Observed difference in percentages (TCZ + PBO minus TCZ + MTX) and the asymptotic Wald 95% CI is presented.
  • Period 2: Randomized Participants (TCZ + MTX) vs Period 2: Randomized Participants (TCZ + PBO) · Cochran-Mantel-Haenszel · p = 0.0663 · Acr 70 response rate difference: -11.6 · 95% CI -22.8 to -0.3Observed difference in percentages (TCZ + PBO minus TCZ + MTX) and the asymptotic Wald 95% CI is presented.
  • Period 2: Randomized Participants (TCZ + MTX) vs Period 2: Randomized Participants (TCZ + PBO) · Acr 70 response rate difference: -8.2 · 95% CI -19.4 to 3.1Observed difference in percentages (TCZ + PBO minus TCZ + MTX) and the asymptotic Wald 95% CI is presented.
SecondaryPercentage of Participants With >/=1.2 Points Increase (Worsening) From Week 24 in DAS28 Score at Week 40 and 52

The DAS28 was derived from assessments of ESR measured in mm/h, TJC28, SJC28, and Patient's global assessment of disease activity according to 100-mm VAS. DAS28 score was calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. DAS28- score could range from 0 to 10, where higher score represented higher disease activity.

Time frame:
Week 24, 40, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With >/=1.2 Points Increase (Worsening) From Week 24 in DAS28 Score at Week 40 and 52
percentage of participantsPeriod 2: Randomized Participants (TCZ + MTX)Period 2: Randomized Participants (TCZ + PBO)
Week 4021.1 ± 0.81628.6 ± 0.822
Week 5226.5 ± 1.12729.9 ± 1.275
Statistical analysis
  • Period 2: Randomized Participants (TCZ + MTX) vs Period 2: Randomized Participants (TCZ + PBO) · Cochran-Mantel-Haenszel · p = 0.2371 · Das28 worsening rate difference: 7.5 · 95% CI -2.4 to 17.3TCZ + PBO minus TCZ + MTX
  • Period 2: Randomized Participants (TCZ + MTX) vs Period 2: Randomized Participants (TCZ + PBO) · Cochran-Mantel-Haenszel · p = 0.4811 · Das28 worsening rate difference: 3.4 · 95% CI -6.9 to 13.7TCZ + PBO minus TCZ + MTX
SecondaryPercentage of Participants With DAS28 Score <2.6 (DAS28 Remission)

The DAS28 was derived from assessments of ESR measured in mm/h, TJC28, SJC28, and Patient's global assessment of disease activity according to 100-mm VAS. DAS28 score was calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. DAS28 score could range from 0 to 10, where higher score represented higher disease activity.

Time frame:
Week 40, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With DAS28 Score <2.6 (DAS28 Remission)
percentage of participantsPeriod 2: Randomized Participants (TCZ + MTX)Period 2: Randomized Participants (TCZ + PBO)
Week 4059.2 ± 0.81649.7 ± 0.822
Week 5255.1 ± 1.12748.3 ± 1.275
Statistical analysis
  • Period 2: Randomized Participants (TCZ + MTX) vs Period 2: Randomized Participants (TCZ + PBO) · Cochran-Mantel-Haenszel · p = 0.1062 · Das28 remission rate difference: -9.5 · 95% CI -20.9 to 1.8TCZ + PBO minus TCZ + MTX
  • Period 2: Randomized Participants (TCZ + MTX) vs Period 2: Randomized Participants (TCZ + PBO) · Cochran-Mantel-Haenszel · p = 0.3611 · Das28 remission rate difference: -6.8 · 95% CI -18.2 to 4.6TCZ + PBO minus TCZ + MTX
SecondaryPercentage of Participants With DAS28 Score </=3.2 (Low DAS28)

The DAS28 was derived from assessments of ESR measured in mm/h, TJC28, SJC28, and Patient's global assessment of disease activity according to 100-mm VAS. DAS28 score was calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. DAS28-ESR score could range from 0 to 10, where higher score represented higher disease activity.

Time frame:
Week 40, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With DAS28 Score </=3.2 (Low DAS28)
percentage of participantsPeriod 2: Randomized Participants (TCZ + MTX)Period 2: Randomized Participants (TCZ + PBO)
Week 4076.9 ± 0.81663.3 ± 0.822
Week 5268.0 ± 1.12762.6 ± 1.275
Statistical analysis
  • Period 2: Randomized Participants (TCZ + MTX) vs Period 2: Randomized Participants (TCZ + PBO) · Cochran-Mantel-Haenszel · p = 0.0228 · Low das28 rate difference: -13.6 · 95% CI -24.0 to -3.3TCZ + PBO minus TCZ + MTX
  • Period 2: Randomized Participants (TCZ + MTX) vs Period 2: Randomized Participants (TCZ + PBO) · Cochran-Mantel-Haenszel · p = 0.3665 · Low das28 rate difference: -5.4 · 95% CI -16.3 to 5.4TCZ + PBO minus TCZ + MTX
SecondaryChange From Week 24 in Bone Erosion Score at Week 40 for Participants in the Magnetic Resonance Imaging (MRI) Substudy

Bones from the wrist regions (carpal bones, distal radius, distal ulna, and metacarpal bases) and the metacarpophalangeal (MCP) joints (metacarpal heads and phalangeal bases) were assessed for erosion via MRI and scored separately based on the proportion of eroded bone compared to the 'assessed bone volume' judged from all available images. Scoring ranged from 0 (no erosion) to 10 (91-100%). Results were summed, resulting in scores from 0 to 80 for the wrist region, 0 to 150 for the MCP joints, and 0 to 230 on aggregate. A negative value for change from Week 24 in bone erosion score indicated an improvement.

Time frame:
Weeks 24, Week 40
Reported as:
Mean · units on a scale
Change From Week 24 in Bone Erosion Score at Week 40 for Participants in the Magnetic Resonance Imaging (MRI) Substudy
units on a scalePeriod 2: Randomized Participants (TCZ + MTX)Period 2: Randomized Participants (TCZ + PBO)
Week 2410.66 ± 11.2179.05 ± 7.926
Change at Week 40-0.10 ± 0.8440.17 ± 1.067
Statistical analysis
  • Period 2: Randomized Participants (TCZ + MTX) vs Period 2: Randomized Participants (TCZ + PBO) · Estimated mean difference: 0.24 · 95% CI -0.21 to 0.68TCZ + PBO minus TCZ + MTX
SecondaryPercentage of Participants With Anti-Therapeutic Antibodies (ATA) to TCZ

Percentage of participants with positive results for ATA against TCZ at Baseline and at any of the post-baseline assessment time-points was reported. Participants positive at any post-baseline time points were participants who had no positivity at baseline for the same assay.

Time frame:
Baseline, Post-baseline (assessed at Weeks 12, 24, 36, 52 and at follow up [Week 60])
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-Therapeutic Antibodies (ATA) to TCZ
percentage of participantsOverall Study Population
Baseline1.8
Post-baseline1.5
SecondaryMean TCZ Serum Concentration
Time frame:
Baseline, Weeks 12, 24, 36, 52 and follow up (Week 60)
Reported as:
Mean · micrograms per milliliter
Mean TCZ Serum Concentration
micrograms per milliliterOverall Study Population
Baseline0.01 ± 0.223
Week 128.66 ± 10.590
Week 2423.38 ± 22.979
Week 3625.58 ± 23.133
Week 5216.46 ± 20.976
Week 606.16 ± 15.768
SecondaryMean Soluble Interleukin-6 (IL-6) Receptor Concentration
Time frame:
Baseline, Weeks 12, 24, 36, 52 and follow up (Week 60)
Reported as:
Mean · nanograms per milliliter
Mean Soluble Interleukin-6 (IL-6) Receptor Concentration
nanograms per milliliterOverall Study Population
Baseline40.4 ± 18.14
Week 12366.4 ± 179.21
Week 24441.3 ± 190.78
Week 36468.9 ± 211.73
Week 52336.3 ± 267.20
Week 60166.8 ± 211.39

Adverse events

Collected over From Baseline up to Week 60. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Overall Study Population—72/713 (10.1%)348/713 (48.8%)
Most frequent serious events
Showing 10 of 81
Most frequent serious events
EventOverall Study Population
PneumoniaInfections and infestations10/713
Myocardial infarctionCardiac disorders5/713
Chest painGeneral disorders5/713
Acute respiratory failureRespiratory, thoracic and mediastinal disorders4/713
CellulitisInfections and infestations3/713
Arthritis infectiveInfections and infestations2/713
DiverticulitisInfections and infestations2/713
UrosepsisInfections and infestations2/713
Angina unstableCardiac disorders2/713
Atrial fibrillationCardiac disorders2/713
Most frequent other events
Most frequent other events
EventOverall Study Population
Alanine aminotransferase increasedInvestigations101/713
Upper respiratory tract infectionInfections and infestations93/713
Hepatic enzyme increasedInvestigations69/713
Aspartate aminotransferase increasedInvestigations65/713
Urinary tract infectionInfections and infestations54/713
NauseaGastrointestinal disorders53/713
Liver function test increasedInvestigations52/713
SinusitisInfections and infestations40/713

Baseline characteristics

Intent-to-treat (ITT) population included all participants who received at least 1 dose of study medication and had at least 1 post-baseline efficacy assessment.

Age, Continuous
Age, Continuous(years)Overall Study Population
Mean55.8 ± 12.31
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study Population
Female556
Male155
08

Study locations

155 sites
  • Pinnacle Research Group; Llc, Central
    Anniston, Alabama 36207, United States
  • Uni Of Alabama,Birmingham; Medicine - Rheumatology
    Birmingham, Alabama 35294, United States
  • Rheumatology Associates of North Alabama
    Huntsville, Alabama 35801, United States
  • Clnical & Translational Reseach Center for Alabama, PC
    Tuscaloosa, Alabama 35406, United States
  • Arizona Arthritis & Rheumatology Associates, P.C.
    Glendale, Arizona 85306, United States
  • Arizona Arthritis & Rheumatology Research, Pllc
    Mesa, Arizona 85202, United States
  • Arizona Arthritis and Rheuma
    Mesa, Arizona 85202, United States
  • Valley Arthritis Care
    Phoenix, Arizona 85027, United States
  • Advanced Arthritis Care & Research
    Scottsdale, Arizona 85258, United States
  • Fort Smith Rheumatology, PC
    Fort Smith, Arkansas 72903, United States
  • CHI St. Vincent Medical Group Hot Springs
    Hot Springs, Arkansas 71913, United States
  • NEA Baptist Clinic
    Jonesboro, Arkansas 72401, United States
  • Little Rock Diagnostic Clinic
    Little Rock, Arkansas 72205, United States
  • Medvin Clinical Research
    Covina, California 91723, United States
  • TriWest Research Associates, LLC
    El Cajon, California 92020, United States
  • St. Jude Hospital Yorba Linda DBA St. Joseph
    Fullerton, California 92835, United States
  • CV Mehta MD Medical Corp
    Hemet, California 92543, United States
  • Valerius Medical Group
    Los Alamitos, California 90720, United States
  • NRC Research Institute
    Orange, California 92868, United States
  • San Diego Arthritis Med Clnc
    San Diego, California 92108, United States
  • C Michael Neuwelt MD Inc
    San Leandro, California 94578, United States
  • Inland Rheumatology; Clinical Trials, Inc.
    Upland, California 91785-1141, United States
  • Medvin Clinical Research
    Whittier, California 90606, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Arthritis Assoc & Osteoporosis; Ctr of Colorado Springs
    Colorado Springs, Colorado 80920, United States
  • Denver Arthritis Clinic
    Denver, Colorado 80230-7127, United States
  • Joao Nascimento
    Bridgeport, Connecticut 06606, United States
  • Clinical Research Center of Ct/Ny
    Danbury, Connecticut 06810, United States
  • Arthritis & Osteoporosis Center Pc
    Hamden, Connecticut 06518, United States
  • New England Research Associates
    Trumbull, Connecticut 06611, United States
  • Rheumatolgy Consultants of Deleware
    Lewes, Delaware 19958, United States
  • Javed Rheumatology Associates, Inc.
    Newark, Delaware 19713, United States
  • Arthritis & Rheumatism; Disease Specialities
    Aventura, Florida 33180, United States
  • Robert Levin, Md; Research Dept
    Dunedin, Florida 34698, United States
  • Precision Research Organization
    Miami Lakes, Florida 33016, United States
  • Suncoast Research Group LLC
    Miami, Florida 33135, United States
  • South Coast Research Center, Inc.
    Miami, Florida 33136, United States
  • Jeffrey Alper M.D Research
    Naples, Florida 34102, United States
  • Rheumatology Associates of Central Florida
    Orlando, Florida 32806, United States
  • Arthritis and Rheumatology Clinic
    Orlando, Florida 32836, United States
  • Arthritis Center Palm Harbor
    Palm Harbor, Florida 34684, United States
  • Arthritis Rsrch of Florida, Inc.
    Palm Harbor, Florida 34684, United States
  • Pinellas Medical Research - Allegry & Rheumatology Associates, LLC
    Saint Petersburg, Florida 33708, United States
  • Sarasota Arthritis Res Center
    Sarasota, Florida 34239, United States
  • West Broward Rheumatology Associates, Inc.
    Tamarac, Florida 33321, United States
  • McIlwain Medical Group
    Tampa, Florida 33613, United States
  • Burnette & Silverfield, MDS
    Tampa, Florida 33614, United States
  • Advanced Clinical Research of Orlando, Inc.
    Winter Garden, Florida 34787, United States
  • North Georgia Rheumatology
    Duluth, Georgia 30096, United States
  • Arthritis Center of North Georgia
    Gainesville, Georgia 30501, United States
  • North Georgia Rheumatology Group, PC
    Lawrenceville, Georgia 30046, United States
  • Institute of Arthritis Research
    Idaho Falls, Idaho 83404, United States
  • Springfield Clinic
    Springfield, Illinois 62703, United States
  • Indiana Uni Medical Center
    Indianapolis, Indiana 46202, United States
  • Diagnostic Rheumatology & Research
    Indianapolis, Indiana 46227, United States
  • Kansas City Internal Medicine
    Overland Park, Kansas 66209, United States
  • Bluegrass Comm Research, Inc.
    Lexington, Kentucky 40515, United States
  • Arthritis & Diabetes Clinic, Inc
    Monroe, Louisiana 71203, United States
  • Klein & Associates, M.D., P.A.
    Hagerstown, Maryland 21740, United States
  • New England Medical Center; Dept. of Medicine, Div. of Rheumatology
    Boston, Massachusetts 02111, United States
  • Phase Iii Clinical Research
    Fall River, Massachusetts 02720, United States
  • Mansfield Medical Center
    Mansfield, Massachusetts 02048, United States
  • Reliant Medical Group, Inc; Rheumatology
    Worcester, Massachusetts 01605, United States
  • UMass Memorial Medical Center
    Worcester, Massachusetts 01605, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01610, United States
  • Advanced Rheumatology, PC
    Lansing, Michigan 48910, United States
  • Fiechtner Research Inc
    Lansing, Michigan 48910, United States
  • Nisus Research/Northern Michigan Hospital
    Petoskey, Michigan 49770, United States
  • Shores Rheumatology
    Saint Clair Shores, Michigan 48081, United States
  • St. Luke's Hospital Association of Duluth
    Duluth, Minnesota 55805, United States
  • St. Paul Rheumatology
    Eagan, Minnesota 55121, United States
  • Arthritis and Osteoporosis; Treatment and Research Center
    Flowood, Mississippi 39232, United States
  • Jackson Arthritis Clinic
    Flowood, Mississippi 39232, United States
  • David S Rosenberg
    Florissant, Missouri 63031, United States
  • Clinical Research Consultants,LLC
    Kansas City, Missouri 64111, United States
  • Clayton Medical Research
    Saint Louis, Missouri 63117, United States
  • Arthritis Consultants
    Saint Louis, Missouri 63141, United States
  • G. T. Kelly, MD
    Las Vegas, Nevada 89128, United States
  • Rheumatology Research Group
    Lebanon, New Hampshire 03756, United States
  • Nashua Rheumatology - Foundation Medical Partners
    Nashua, New Hampshire 03060, United States
  • Arthritis and Osteoporosis Associates
    Manalapan, New Jersey 07726, United States
  • Atlantic Coast Rheumatology
    Toms River, New Jersey 08755, United States
  • Ocean Rheumatology
    Toms River, New Jersey 08775, United States
  • Arthritis Rheumatic & Back Disease Associates
    Voorhees, New Jersey 08043, United States
  • Cooper Cancer Institute
    Voorhees, New Jersey 08043, United States
  • Albuquerque Clinical Trials
    Albuquerque, New Mexico 87102, United States
  • Arthritis and Osteoporosis Associates of New Mexico
    Las Cruces, New Mexico 88011, United States
  • The Center for Rheumatology
    Albany, New York 12203, United States
  • Arthritis & Osteoporosis Center
    Brooklyn, New York 11201, United States
  • Manhasset Rheumatology
    Manhasset, New York 11030, United States
  • Manhattan Medical Reserach
    New York, New York 10016, United States
  • Buffalo Rheumatology Associates
    Orchard Park, New York 14127, United States
  • Office of Premier Chatpar Md
    Plainview, New York 11803, United States
  • Rheumatology Associates of Long Island
    Smithtown, New York 11787, United States
  • Arthritis Health Associates
    Syracuse, New York 13210, United States
  • Asheville Arthritis & Osteoporosis Center, PA
    Asheville, North Carolina 28803, United States
  • Carolina Bone & Joint P.A.
    Charlotte, North Carolina 28210, United States
  • Triangle Orthopaedics Associates, P.A.
    Durham, North Carolina 27704, United States
  • Medication Management
    Greensboro, North Carolina 27408, United States
  • PMG Research of Hickory LLC
    Hickory, North Carolina 28602, United States

Showing the first 100 of 155 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kremer JM, Rigby W, Singer NG, Birchwood C, Gill D, Reiss W, Pei J, Michalska M. Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial. Arthritis Rheumatol. 2018 Aug;70(8):1200-1208. doi: 10.1002/art.40493. Epub 2018 Jun 14. PubMed 29575803 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in Oct 2016, 35 months.

Results were first posted in Dec 2017, 1 year 2 months after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 35 months is above that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2013
First posted
May 17, 2013
StartActual
Nov 7, 2013
Primary completionActual
Oct 14, 2016
CompletionActual
Oct 14, 2016
Results first posted
Dec 26, 2017
Last update
Dec 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01855789
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 17, 2013
Start date
Nov 7, 2013
Primary completion
Oct 14, 2016
Completion
Oct 14, 2016
Results posted
Dec 26, 2017
Last update
Dec 26, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion